HK1170486A1 - Useful pharmaceutical salts of 7-[(3r, 4r)-3-hydroxy-4-hydroxymethyl- pyrrolidin-1-ylmethyl]-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-one 7-[(3r4r)-3--4---1-]-35--[32-d] -4- - Google Patents

Useful pharmaceutical salts of 7-[(3r, 4r)-3-hydroxy-4-hydroxymethyl- pyrrolidin-1-ylmethyl]-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-one 7-[(3r4r)-3--4---1-]-35--[32-d] -4-

Info

Publication number
HK1170486A1
HK1170486A1 HK12111259.9A HK12111259A HK1170486A1 HK 1170486 A1 HK1170486 A1 HK 1170486A1 HK 12111259 A HK12111259 A HK 12111259A HK 1170486 A1 HK1170486 A1 HK 1170486A1
Authority
HK
Hong Kong
Prior art keywords
pyrrolo
pyrrolidin
pyrimidin
ylmethyl
dihydro
Prior art date
Application number
HK12111259.9A
Other languages
English (en)
Chinese (zh)
Inventor
加里‧巴特利
托馬斯‧克利里
約翰‧
‧郎
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of HK1170486A1 publication Critical patent/HK1170486A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK12111259.9A 2009-03-24 2012-11-07 Useful pharmaceutical salts of 7-[(3r, 4r)-3-hydroxy-4-hydroxymethyl- pyrrolidin-1-ylmethyl]-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-one 7-[(3r4r)-3--4---1-]-35--[32-d] -4- HK1170486A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16280509P 2009-03-24 2009-03-24
PCT/US2010/028490 WO2010111381A2 (en) 2009-03-24 2010-03-24 Useful pharmaceutical salts of 7-[(3r, 4r)-3-hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-one

Publications (1)

Publication Number Publication Date
HK1170486A1 true HK1170486A1 (en) 2013-03-01

Family

ID=42781851

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12111259.9A HK1170486A1 (en) 2009-03-24 2012-11-07 Useful pharmaceutical salts of 7-[(3r, 4r)-3-hydroxy-4-hydroxymethyl- pyrrolidin-1-ylmethyl]-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-one 7-[(3r4r)-3--4---1-]-35--[32-d] -4-

Country Status (18)

Country Link
US (1) US8501753B2 (xx)
EP (1) EP2411394B1 (xx)
JP (1) JP5766687B2 (xx)
KR (1) KR101763672B1 (xx)
CN (1) CN102448963B (xx)
AU (1) AU2010230008B2 (xx)
BR (1) BRPI1006534B1 (xx)
CA (1) CA2755950C (xx)
EA (1) EA020931B1 (xx)
ES (1) ES2519568T3 (xx)
HK (1) HK1170486A1 (xx)
IL (1) IL215298A (xx)
MX (1) MX2011009928A (xx)
NZ (1) NZ595590A (xx)
PL (1) PL2411394T3 (xx)
RU (1) RU2489435C2 (xx)
SG (1) SG174517A1 (xx)
WO (1) WO2010111381A2 (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA020659B1 (ru) 2008-04-23 2014-12-30 Джилид Сайэнс, Инк. 1'-замещённые карбануклеозидные аналоги для противовирусной терапии
CA2773773C (en) 2009-09-21 2019-04-23 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs
KR102108864B1 (ko) 2010-07-19 2020-05-12 길리애드 사이언시즈, 인코포레이티드 부분입체 이성질성으로 순수한 포스포라미데이트 전구약물의 제조 방법
SI2595980T1 (sl) 2010-07-22 2014-11-28 Gilead Sciences, Inc. Postopki in sestavki za zdravljenje paramyxoviridae virusnih infekcij
AR090699A1 (es) * 2012-04-18 2014-12-03 Biocryst Pharm Inc Compuestos inhibidores de la actividad de la arn polimerasa viral
TWI740546B (zh) 2014-10-29 2021-09-21 美商基利科學股份有限公司 製備核糖苷的方法
MA52371A (fr) 2015-09-16 2021-09-22 Gilead Sciences Inc Méthodes de traitement d'infections dues aux coronaviridae
CN116036112A (zh) 2017-03-14 2023-05-02 吉利德科学公司 治疗猫冠状病毒感染的方法
CA3178212A1 (en) 2017-05-01 2018-11-08 Gilead Sciences, Inc. Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
CN111093627B (zh) 2017-07-11 2024-03-08 吉利德科学公司 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物
AU2021214911A1 (en) 2020-01-27 2022-07-21 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
US11613553B2 (en) 2020-03-12 2023-03-28 Gilead Sciences, Inc. Methods of preparing 1′-cyano nucleosides
EP4132651A1 (en) 2020-04-06 2023-02-15 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
WO2021243157A1 (en) 2020-05-29 2021-12-02 Gilead Sciences, Inc. Remdesivir treatment methods
BR112022026321A2 (pt) 2020-06-24 2023-01-17 Gilead Sciences Inc Análogos de 1'-ciano nucleosídeo e usos dos mesmos
WO2022047065A2 (en) 2020-08-27 2022-03-03 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
KR102580079B1 (ko) * 2020-10-29 2023-09-19 한양대학교 산학협력단 기생 인덕턴스 감소를 위한 적층형 회로 구조체
GB202110403D0 (en) * 2021-07-20 2021-09-01 Laevoroc Immunology Ulodesine Salt
EP4320128A1 (en) 2022-03-02 2024-02-14 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870732A (en) 1973-08-21 1975-03-11 Velsicol Chemical Corp Mixed salts of aluminum
US5386031A (en) * 1993-12-15 1995-01-31 Warner-Lambert Company Process for the synthesis of 2-amino-3,5-dihydro-7-substituted-4H-pyrrolo[3,]pyrimidin-4-ones
PE78999A1 (es) * 1997-05-29 1999-09-08 Novartis Ag 2-amino-7-(2-hidroxietilo 1-sustituido)-3,5-dihidropirrolo [3,2-d] pirimidin-4 onas
RU2330042C2 (ru) * 2002-08-21 2008-07-27 Альберт Эйнштейн Колледж Оф Медсин Оф Йешива Юниверсити Ингибиторы нуклеозидфосфорилаз и нуклеозидаз
NZ523970A (en) * 2003-02-04 2005-02-25 Ind Res Ltd Process for preparing inhibitors of nucleoside phoshorylases and nucleosidases
NZ544187A (en) * 2005-12-15 2008-07-31 Ind Res Ltd Deazapurine analogs of 1'-aza-l-nucleosides

Also Published As

Publication number Publication date
US8501753B2 (en) 2013-08-06
NZ595590A (en) 2013-11-29
CA2755950C (en) 2017-04-25
EA201190205A1 (ru) 2012-06-29
PL2411394T3 (pl) 2015-01-30
SG174517A1 (en) 2011-10-28
IL215298A (en) 2017-04-30
RU2489435C2 (ru) 2013-08-10
IL215298A0 (en) 2011-12-29
EP2411394B1 (en) 2014-08-06
CN102448963B (zh) 2015-06-17
EA020931B1 (ru) 2015-02-27
WO2010111381A2 (en) 2010-09-30
MX2011009928A (es) 2012-03-16
AU2010230008B2 (en) 2015-06-04
BRPI1006534A2 (pt) 2016-08-02
AU2010230008A1 (en) 2011-10-06
JP5766687B2 (ja) 2015-08-19
KR20120005466A (ko) 2012-01-16
WO2010111381A3 (en) 2011-03-31
KR101763672B1 (ko) 2017-08-01
JP2012521992A (ja) 2012-09-20
EP2411394A4 (en) 2012-08-15
ES2519568T3 (es) 2014-11-07
US20120165526A1 (en) 2012-06-28
RU2011141212A (ru) 2013-04-27
CA2755950A1 (en) 2010-09-30
BRPI1006534B1 (pt) 2021-05-25
EP2411394A2 (en) 2012-02-01
CN102448963A (zh) 2012-05-09

Similar Documents

Publication Publication Date Title
HK1170486A1 (en) Useful pharmaceutical salts of 7-[(3r, 4r)-3-hydroxy-4-hydroxymethyl- pyrrolidin-1-ylmethyl]-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-one 7-[(3r4r)-3--4---1-]-35--[32-d] -4-
IL266285B (en) Methods for the production of thiano [d – 3,2] pyrimidine compounds
EP2491043A4 (en) 2,7-SUBSTITUTED THIEN [3,2-D] PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS
ZA201306545B (en) 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of betasecretase (bace)
IL211191A (en) Oxalate salt of (3as, 4r, 6s, 6ar) –6– (2– hydroxyethoxy) –2,2 – dimethyl tetrahydro –3 ah– cyclopenta [d] [1,3] dioxol – 4 – amine
IL227087A0 (en) (2s,5r)-6-(benzyloxy/allyloxy)-7-oxo-6,1-diazabicyclo[1.2.3]octane-2-carboxylates, process for their preparation and use of (2s,5r)-tert-butyl-6 -(benzyloxy)-7-oxo-6,1-diazabicyclo[1.2.3]octane-2-carboxylate for the preparation of an anti-infective drug
HK1204619A1 (en) Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrim as lrrk2 inhibitors lrrk2 4-()-7h-[23-d]
ZA201200982B (en) Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
HK1170241A1 (zh) 可用作 的抑制劑的化合物的製備方法
IL225622A0 (en) Furo[3, 2-di]pyrimidine compounds
RS55038B1 (sr) Biciklični hetrociklil derivati kao inhibitori fgfr kinaza za terapeutsku primenu
IL218032A0 (en) Imidazopyridine or imidazopyrimidine derivatives as phosphodiesterase 10a inhibitors
ZA201105896B (en) [1,2,4] triazolo [1,5-a] pyridines as kinase inhibitors
HK1201441A1 (en) Process for the preparation of substituted pyrimidine derivatives
ZA201202097B (en) Crystalline forms of substituted pyrazolopyrimidines
EP2511276A4 (en) PYRROLO [2,3-D] PYRIMIDINE DERIVATIVE
HK1171759A1 (zh) 螺酮縮醇衍生物的製備方法
ZA200904192B (en) 7-substituted purine derivatives for immunosuppression